HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 7, 2024 /CNW/ – HLS Therapeutics Inc. (“HLS” or the “Company”) (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.

A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:

 

Name of Nominee

Votes Cast

FOR

% of Vote Cast

FOR

Votes

WITHHELD

% of Votes

WITHHELD

John Welborn

18,209,962

88.85

2,284,420

11.15

Craig Millian

19,959,739

97.39

534,643

2.61

John Hanna

19,135,935

93.37

1,358,447

6.63

Rodney Hill

19,959,554

97.39

534,828

2.61

Laura Brege

19,118,129

93.28

1,376,253

6.72

Norma Beauchamp

16,442,226

80.23

4,052,156

19.77

Kyle Dempsey

19,032,703

92.87

1,461,679

7.13

Christian Roy

19,135,933

93.37

1,358,449

6.63

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company’s auditors with 21,098,117 votes (100%) cast “for” and 137 votes (0%) withheld.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS’s focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS’s management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

Featured image: © healthhkD

Disclaimer